Tag: Tandem Diabetes Care
Tandem’s AID cleared for pregnancies complicated by Type 1 diabetes mellitus
April 29, 2026HME News Staff
SAN DIEGO – Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by Type 1 diabetes mellitus. Control-IQ+ powers both insulin delivery systems from Tandem – the t:slim X2 and Tandem Mobi, the first and only commercially available AID systems cleared for use during pregnancy in the United States. “Glycemic goals are tighter during pregnancy,” said...
Tandem’s t:slim integrates with FreeStyle Libre 3 Plus
October 29, 2025HME News Staff
SAN DIEGO – Tandem Diabetes has announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States. This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes worldwide, the company says. “With this integration, we expand...
Diabetes advocates rally for Medicare reform on insulin pump access
September 26, 2025Theresa Flaherty, Managing Editor
SAN DIEGO – Diabetes stakeholders will meet with CMS in October to urge the agency to update its National Coverage Determination (NCD) guidance on who qualifies for an insulin pump to better reflect current clinical practice.
CMS currently requires a low C-peptide level for insulin pump coverage, which excludes many people with Type 2 diabetes from obtaining an automated insulin delivery (AID) system, even if they were already been benefiting from the technology prior to moving to...
Study: Tandem’s AID can lower A1c in certain Type 2 diabetes patients
September 18, 2025HME News Staff
SAN DIEGO – Tandem Diabetes Care’s Control-IQ+ automated insulin delivery system can lower HbA1c’s in adults with insulin-treated Type 2 diabetes, according to a new study published in the American Diabetes Association’s Diabetes Care. The study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," is a sub-analysis from the 2IQP randomized, controlled trial. Of the 319 participants in the 2IQP trial, 254 were included...
In brief: Sleep think tank, Medicaid managed care fraud, diabetes reorg
September 5, 2025HME News Staff
SAN DIEGO – Resmed has launched the Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health.
The company says the Sleep Institute partners with clinicians, researchers, policymakers and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions and elevate sleep as a global health priority.
“Sleep Institute reflects...
Tandem receives authorization to distribute t:slim app in Canada
September 4, 2025HME News Staff
SAN DIEGO – Tandem Diabetes Care has received Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone and to wirelessly upload their pump data to the cloud-based Tandem Source platform. The app is expected to be available later this year. “This authorization demonstrates our dedication to expanding Tandem’s global offerings and...
Tandem integrates, partners with Abbott
June 23, 2025HME News Staff
SAN DIEGO – Tandem Diabetes Care has announced that the Tandem t:slimX2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. The company has initiated an early access program in the United States and intends to scale availability in the second half of 2025. “Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize...
Tandem sees sales increase in Q1
May 1, 2025HME News Staff
SAN DIEGO – Tandem Diabetes Care reported that worldwide sales increased to $234.4 million for its first quarter 2025, an increase of 22% compared to the same quarter in 2024. Pump sales in the U.S. grew by 19% on a GAAP basis and 17% on a non-GAAP basis, on strong shipment growth and average selling price improvement, with the company shipping more than 17,000 pumps in the U.S. and 11,000 outside the U.S. “The strength of our first quarter performance was driven by more than 20% worldwide...
In brief: Not guilty verdict, Tandem Diabetes recall, Healthcare Growth Group launch
August 23, 2024HME News Staff
SAN ANTONIO – Kuba Zarobkiewicz and Anthony Fermin, owners of DME companies, have been found not guilty of health care fraud, violations of the Anti-Kickback Statute and conspiracy charges by a federal jury.
Zarobkiewicz and Fermin ran brace businesses through multiple companies beginning in 2020 and then voluntarily shut them down in late 2021. They began cooperating with a law enforcement investigation in September 2022 and then were charged in December 2022 in the Western District...
Tandem offers update on recall
August 21, 2024HME News Staff
SAN DIEGO – Tandem Diabetes Care on Aug. 9 emailed notices to customers impacted by a recall of its Apple OS t:connect mobile app. The recall, issued in March, relates to an issue that can cause rapid depletion of a user’s t:slim X2 insulin pump battery, causing the insulin pump to shut down sooner than expected. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release. Tandem strongly...